BIO Brings Industry Leaders, Investors Together for æ2000 Reasons to Invest in Biotechnology'
WASHINGTON, D.C. (Oct. 22, 1999) -- The BiotechnologyIndustry Organization will host its second annual CEO & Investor Conference, ô2000 Reasons to Invest in Biotechnology,ö at the Waldorf=Astoria in New York Feb. 15-16, 2000.
The two-day event will include 12 investor sessions, six CEO roundtables, networking receptions, industry luncheons and more than 100 company presentations.
ôLast year's conference was a huge success, drawing close to 800 people almost twice the number expected,ö said BIO President Carl B. Feldbaum. ôThe upcoming conference is expected to attract an even larger group of investors, biotech leaders, licensing executives and news media.ö
Biotech CEOs will participate in the investor sessions and each session will focus on a different therapeutic approach or disease. Industry analysts will act as moderators.
The interactive roundtables will highlight issues that impact the growth of the industry and the health of individual companies. CEOs will share their experiences and expertise in creative financing, growth strategies, accessing foreign capital, industry consolidation, moving forward with clinical trials and other concerns of biotech leaders and investors.
The conference will give investors the opportunity to evaluate companies with complementary and competitive technologies. In turn, CEOs will have the chance to forge relationships with investment firms active in the biotechnology industry. Among the sponsors are Adams, Harkness & Hill; Lehman Brothers; Palmer & Dodge; PricewaterhouseCoopers LLP; Punk, Zeigel & Company; Vector Securities International; Credit Suisse First Boston; Hambrecht & Quist; LedbetterStevens International; McKinsey & Company; Raymond James and Associates; and Warburg Dillon Read.
Press registration is complimentary. To register contact Charles Craig at BIO (202-962-9200).
BIO represents more than 830 biotechnology companies, academic institutions and state biotech centers in 47 states and 26 nations. BIO members are involved in the research and development of health care, agricultural, industrial and environmental biotechnology products.